US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

157.47

+1.230.79%

Post-market: 157.500.0300+0.02%18:47 EDT

Volume:419.58K

Turnover:66.58M

Market Cap:507.76M

PE:- -

High:161.26

Open:157.46

Low:155.50

Close:156.24

52wk High:198.18

52wk Low:32.55

Shares:3.22M

Float Shares:3.22M

Volume Ratio:0.60

T/O Rate:13.01%

Dividend:1.34

Dividend Rate:0.85%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts’ Top Healthcare Picks: Oneview Healthcare Chess Depository Interests repr 1 (ONVVF), Spyre Therapeutics (SYRE)

Ispire Technology Highlights Economic Impact of FDA's New E-Cigarette Flavor Guidance, Foresees $50 Billion Market Unlock and Asset Value Surge

Viemed Healthcare Releases Updated March 2026 Investor Presentation

Health Care Up as Biotech Rebounds - Health Care Roundup

'Healthcare is important to me': I'm worried about relocating to Florida from New Jersey. Are hospitals there under stress?

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA)

NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug

Benzinga_recent_news

Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)

GE Healthcare’s LUMINA Trial Positions New MRI Contrast Agent for Future Growth

Health Care Roundup: Market Talk

De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi

Fidia Advances POC Financing with New Share Issue to GGHL

Fortis Healthcare Reports No Requests Under SEBI Physical Share Transfer Window

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears

Simply Wall St.

Sector Update: Health Care

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Stevanato Group (STVN) and BioNTech SE (BNTX)

Press Release: LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LABU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":157.47,"timestamp":1773777600000,"preClose":156.24,"halted":0,"volume":419583,"hourTrading":{"tag":"盘后","latestPrice":157.5,"preClose":157.47,"latestTime":"18:47 EDT","volume":1326,"amount":208324.63782,"timestamp":1773787674274,"change":0.03,"changeRate":0.000191,"amplitude":0.010161},"delay":0,"changeRate":0.00787250384024571,"floatShares":3224486,"shares":3224486,"eps":0,"marketStatus":"Post-Mkt","change":1.23,"latestTime":"03-17 18:48:28 EDT","open":157.46,"high":161.26,"low":155.5,"amount":66581310.171840005,"amplitude":0.036866,"askPrice":157.55,"askSize":150,"bidPrice":156.6,"bidSize":100,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773792000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":156.24,"sharesOutstanding":3074486,"nav":149.06,"aum":480642683.13,"dividendRate":0.008533,"bidAskSpread":0.002274,"preHourTrading":{"tag":"盘前","latestPrice":157.98,"preClose":156.24,"latestTime":"09:28 EDT","volume":3731,"amount":579161.18988,"timestamp":1773754129536,"change":1.74,"changeRate":0.011137,"amplitude":0.022721},"postHourTrading":{"tag":"盘后","latestPrice":157.5,"preClose":157.47,"latestTime":"18:47 EDT","volume":1326,"amount":208324.63782,"timestamp":1773787674274,"change":0.03,"changeRate":0.000191,"amplitude":0.010161},"volumeRatio":0.600833,"impliedVol":1.0319,"impliedVolPercentile":0.8526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3224486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.600833,"shares":3224486,"dividePrice":1.3437,"high":161.26,"amplitude":0.036866,"preClose":156.24,"low":155.5,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":157.47,"committee":-0.2,"eps":0,"divideRate":0.008533,"volume":419583,"delay":0,"ttmEps":0,"open":157.46,"prevYearClose":159.39,"prevWeekClose":148.85,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":171.5,"twentyDayClose":162.07,"sixtyDayClose":156.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620557415","title":"Analysts’ Top Healthcare Picks: Oneview Healthcare Chess Depository Interests repr 1 (ONVVF), Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620557415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620557415?lang=en_us&edition=fundamental","pubTime":"2026-03-17 08:40","pubTimestamp":1773708011,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oneview Healthcare Chess Depository Interests repr 1...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-oneview-healthcare-chess-depository-interests-repr-1-onvvf-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-oneview-healthcare-chess-depository-interests-repr-1-onvvf-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","XLV","BK4585","BK4167","BK4139","LABU","ONVVF","BK4581","SYRE","BK4588"],"gpt_icon":0},{"id":"1142698988","title":"Ispire Technology Highlights Economic Impact of FDA's New E-Cigarette Flavor Guidance, Foresees $50 Billion Market Unlock and Asset Value Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1142698988","media":"Stock News","labels":["policyRegulatory","economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142698988?lang=en_us&edition=fundamental","pubTime":"2026-03-17 08:32","pubTimestamp":1773707576,"startTime":"0","endTime":"0","summary":"Ispire Technology Inc. (ISPR.US) emphasized today that the U.S. Food and Drug Administration's (FDA) newly released draft guidance on evidence requirements for Premarket Tobacco Product Applications...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","ISPR","BK1589","BK4075","BK1580","BK4585","06969","BK1242"],"gpt_icon":0},{"id":"2620924484","title":"Viemed Healthcare Releases Updated March 2026 Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2620924484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620924484?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:20","pubTimestamp":1773696043,"startTime":"0","endTime":"0","summary":"Viemed Healthcare ( ($VMD) ) just unveiled an announcement. Viemed Healthcare has released a new investor deck dated March 2026, which it plans to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/viemed-healthcare-releases-updated-march-2026-investor-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/viemed-healthcare-releases-updated-march-2026-investor-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4137","BK4581","BK4588","HCSG","LU0029874061.USD","XBI","LU0128526141.USD","XLV"],"gpt_icon":0},{"id":"2620644494","title":"Health Care Up as Biotech Rebounds - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2620644494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620644494?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:59","pubTimestamp":1773694740,"startTime":"0","endTime":"0","summary":"Health-care companies rose as a flight from high-risk market areas such as biotechnology slowed.The iShares Nasdaq Biotechnology exchange-traded fund, a basket of biotech firms, ticked up roughly 1%, but remains in the red for the year to date.British drugmaker AstraZeneca said it received European Union approval for its Imfinzi drug as a treatment for early-stage gastric and gastroesophageal cancers.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","XBI","BK4588","LABU","BK4585","BK4581"],"gpt_icon":0},{"id":"2620697494","title":"'Healthcare is important to me': I'm worried about relocating to Florida from New Jersey. Are hospitals there under stress?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620697494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620697494?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:58","pubTimestamp":1773694680,"startTime":"0","endTime":"0","summary":"MW 'Healthcare is important to me': I'm worried about relocating to Florida from New Jersey. Are hospitals there under stress?'The issue is not the weather, high insurance premiums or rising maintenance fees'. \"The hospitals in the New York/New Jersey area are outstanding.\" . I'm considering relocating from New Jersey to Florida, condo to condo. The cost of living - especially property taxes - can be challenging here. When you no longer have children in the school system, it's hard to justify the high property taxes in certain towns.The hospitals in the New York/New Jersey area are outstanding. As a senior, healthcare is important to me, and I'm thinking twice about moving. Unfortunately, I cannot afford to maintain two residences. I would welcome hearing your thoughts.Metropolitan areas tend to be better served. \"Rural hospitals continue to operate under significant financial pressure, with margins well below the national median and a growing share at immediate risk of closure,\" Medic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LU0029874061.USD","LABU","BK4588","LU0128526141.USD","BK4137","HCSG","BK4585","BK4581","XBI"],"gpt_icon":0},{"id":"2620410493","title":"Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620410493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620410493?lang=en_us&edition=fundamental","pubTime":"2026-03-17 02:00","pubTimestamp":1773684030,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tarsus Pharmaceuticals (TARS – Research Report) and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tarsus-pharmaceuticals-tars-and-olema-pharmaceuticals-olma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tarsus-pharmaceuticals-tars-and-olema-pharmaceuticals-olma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4007","OLMA","HCSG","XLV","LU0029874061.USD","BK4585","BK4588","LABU","BK4139","TARS","BK4581","XBI","LU0128526141.USD","BK4137"],"gpt_icon":0},{"id":"2620749845","title":"NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749845","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749845?lang=en_us&edition=fundamental","pubTime":"2026-03-17 01:35","pubTimestamp":1773682500,"startTime":"0","endTime":"0","summary":"The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Agitated-Depression-Mentioned.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Agitated-Depression-Mentioned.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","LABU","BK4585","BK4588","SMA"],"gpt_icon":0},{"id":"2620233498","title":"Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2620233498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620233498?lang=en_us&edition=fundamental","pubTime":"2026-03-17 01:25","pubTimestamp":1773681917,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a B...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-biomarin-strong-early-voxzogo-data-real‑world-durability-and-underpenetrated-achondroplasia-opportunity-drive-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-biomarin-strong-early-voxzogo-data-real‑world-durability-and-underpenetrated-achondroplasia-opportunity-drive-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XLV","BK4581","XBI","LABU","BK4588"],"gpt_icon":0},{"id":"2620460826","title":"Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460826?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:40","pubTimestamp":1773679205,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – Research Report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","BK4588","LU0029874061.USD","MLYS","XBI","XLV","APRE","BK4581","BK4139","LU0128526141.USD","HCSG","LABU"],"gpt_icon":0},{"id":"2620446033","title":"GE Healthcare’s LUMINA Trial Positions New MRI Contrast Agent for Future Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620446033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620446033?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:31","pubTimestamp":1773678700,"startTime":"0","endTime":"0","summary":"Ge Healthcare Technologies Inc. ($GEHC) announced an update on their ongoing clinical study. The LUMINA trial is a Phase 2/3 study run by GE Health...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ge-healthcares-lumina-trial-positions-new-mri-contrast-agent-for-future-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ge-healthcares-lumina-trial-positions-new-mri-contrast-agent-for-future-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1084165304.USD","LU1093756168.USD","LU0820561909.HKD","XLV","LU1366192091.USD","LU2168564149.EUR","LU0353189763.USD","LU1066051811.HKD","LU2756315318.SGD","BK4501","LU0943347566.SGD","LU0267386448.USD","BK4585","LU0157215616.USD","LU0640476718.USD","BK4581","LU0354030511.USD","LABU","HCSG","LU1366333091.USD","LU2264538146.SGD","LU1551013425.SGD","LU2168563687.JPY","LU2087625088.SGD","BK4187","BK4566","BK4588","LU0077335932.USD","LU0354030438.USD","LU1551013342.USD","LU0128526141.USD","LU0868494617.USD","LU1280957306.USD","LU2168564495.EUR","XBI","LU0689472784.USD","BK4206","LU1066051498.USD","BK4137","LU1261432733.SGD","LU1988902786.USD","LU2756315664.SGD","GE","BK4543","LU1093756325.SGD","LU2168564065.EUR","LU0820562030.AUD","LU1066053197.SGD","LU0820561818.USD","LU2168564222.USD"],"gpt_icon":0},{"id":"2620674214","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620674214","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620674214?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:20","pubTimestamp":1773678000,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0305 ET - Q&M Dental Group  may benefit from potential completion of mergers and acquisitions, CGS International's Tay Wee Kuang says in a research report. On March 11, it unveiled a memorandum of understanding to acquire an Australian dental group for a consideration to be fulfilled on part-cash and part-shares basis, the analyst notes. By applying similar transaction details to the dental healthcare group's Thailand MOU and Singapore MOU announced on Oct. 15, 2025, and March 4, 2026, respectively, the brokerage estimates completion of the three M&As to boost 2027 EPS by 126.7%. CGS International raises the stock's target price to S$0.68 from S$0.49 with an unchanged add rating. Shares are 1.8% lower at S$0.545. (ronnie.harui","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","LABU","BK4581","BK4585","XBI"],"gpt_icon":0},{"id":"2619462292","title":"De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2619462292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619462292?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:35","pubTimestamp":1773675318,"startTime":"0","endTime":"0","summary":"Savara, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/de-risked-path-to-market-and-concentrated-rare-disease-opportunity-support-buy-rating-on-savaras-molbreevi-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/de-risked-path-to-market-and-concentrated-rare-disease-opportunity-support-buy-rating-on-savaras-molbreevi-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4588","BK4585","XLV","XBI","LABU"],"gpt_icon":0},{"id":"2619646224","title":"Fidia Advances POC Financing with New Share Issue to GGHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2619646224","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619646224?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:34","pubTimestamp":1773675294,"startTime":"0","endTime":"0","summary":"Fidia Spa ( ($IT:FDA) ) has provided an announcement. Fidia S.p.A. has converted three bonds from the fourth tranche of its 2026 convertible bond w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fidia-advances-poc-financing-with-new-share-issue-to-gghl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fidia-advances-poc-financing-with-new-share-issue-to-gghl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4585","VGT"],"gpt_icon":0},{"id":"2619464869","title":"Fortis Healthcare Reports No Requests Under SEBI Physical Share Transfer Window","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464869","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619464869?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:33","pubTimestamp":1773671614,"startTime":"0","endTime":"0","summary":"Fortis Healthcare Ltd. ( ($IN:FORTIS) ) just unveiled an announcement. Fortis Healthcare has informed the stock exchanges about the status of a spe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fortis-healthcare-reports-no-requests-under-sebi-physical-share-transfer-window?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fortis-healthcare-reports-no-requests-under-sebi-physical-share-transfer-window?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0029874061.USD","BK4585","LU0128526141.USD","XBI","XLV","BK4581","LABU","HCSG","BK4137"],"gpt_icon":0},{"id":"2619961469","title":"Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619961469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619961469?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:50","pubTimestamp":1773669007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","BK4585","BK4611","LABU","BK4581","BK4588","LU0128526141.USD","BEAM","LU1861558580.USD","PTHS","LU1861559042.SGD","BK4137","BK4505","BK4535","BK4139","XBI","BK4112","BK4556","LU0029874061.USD","BLSX"],"gpt_icon":0},{"id":"2619469692","title":"Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2619469692","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619469692?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:42","pubTimestamp":1773668520,"startTime":"0","endTime":"0","summary":"On Friday, the U.S. Food and Drug Administration  approved Novartis AG’s  Cosentyx for younger patients.The approval covers pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa .HS is a chronic, systemic inflammatory skin disease that causes recurring boil-like lesions, which can rupture into painful wounds and lead to scarring.HS affects as many as1 in 100 people worldwide and often begins around puberty.\"With more than a decade of real-world experience across multiple autoimmune diseases, Cosentyx is a well-established treatment option that many physicians trust,\" said Victor Bultó, President, Novartis US.The studies and pharmacokinetic modeling support the use of Cosentyx in patients aged 12+ with moderate to severe HS weighing 30 kg or more. Researchers extrapolated this modeling from adult HS and psoriasis clinical trials, as well as pediatric clinical trial data from other approved indications.Dosing analysis also supports the approval and predic","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Atopic-Dermatitis-Photo-via-Shutterstock.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Atopic-Dermatitis-Photo-via-Shutterstock.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/03/51269251/novartis-advances-dermatology-portfolio-with-cosentyx-fda-approval-for-pediatric-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51269251/novartis-advances-dermatology-portfolio-with-cosentyx-fda-approval-for-pediatric-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4578","NVS","IE00BFTCPJ56.SGD","BK4007","IE0002141913.USD","BK4585","LU0320765489.SGD","BK4532","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0208291251.USD","LABU","LU0070302665.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD"],"gpt_icon":0},{"id":"2619464244","title":"Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464244","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619464244?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:10","pubTimestamp":1773666627,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) is back on investors’ radar after Deerfield Management Company added 418,538 shares in the fourth quarter, as the market watches an FDA priority review decision for lead drug candidate atacicept.\nSee our latest analysis for Vera Therapeutics.\nAt a share price of $39.96, Vera’s recent 7 day share price return of 2.54% sits against a 30 day share price return decline of 5.35% and a 90 day share price return decline of 17.27%. The 1 year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4539","VERA","LU2324357040.USD","DCF","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2619446552","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2619446552","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619446552?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:02","pubTimestamp":1773666136,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 0.5%.CytomX Therapeutics  shares were up more than 50% after the company said a phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","IBB","XBI","XLV","BK4581","CTMX","BK4139","LABU"],"gpt_icon":0},{"id":"2619071468","title":"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Stevanato Group (STVN) and BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619071468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619071468?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:40","pubTimestamp":1773664806,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ascendis Pharma (ASND – Research Report), Stevanato Group (STVN –...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-stevanato-group-stvn-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-stevanato-group-stvn-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","ASND","BK4551","HCSG","BK4588","XLV","BK4539","BK4121","BK4139","LU0320765992.SGD","BK4585","BK4535","BK4581","BK4137","LU0029874061.USD","BK4548","LU0128526141.USD","XBI","LU0109394709.USD","BK4568","LU0889565916.HKD","LABU","STVN"],"gpt_icon":0},{"id":"2619645000","title":"Press Release: LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645000","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619645000?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:01","pubTimestamp":1773662460,"startTime":"0","endTime":"0","summary":"NEW YORK, March 16, 2026  -- LifeMD, Inc. , a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition.\"I have spent my career partnering with management teams, boards, and investors to build the financial infrastructure that enables high-growth companies to scale efficiently and create lasting value,\" said Mr. Kavthekar. \"LifeMD is at an inflection point, with a vertically integrated platform, expanding insurance capabilities, and a commitment to AI-driven innovation that can meaningfully improve patient outcomes while driving operating lever","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","XLV","LU0128526141.USD","LABU","LU0029874061.USD","LFMD","BK4137","BK4585","BK4588","XBI","BK4167","HCSG","BK4183","BK4120","TISI","BK4581","R"],"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":3,"totalSize":422,"code":"91000000","status":"200"}]}}